Novo Nordisk unveils promising PhIII data for hemophilia A treatment; Diabetics are paying twice as much for meds;

@FiercePharma: Top-read on FP Tuesday: Shaky Dendreon loses its CEO as debt payments loom. Article | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes.  More | Follow @TracyStaton

@EricPFierce: ICYMI from FiercePharmaManufacturing: New #FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. Story | Follow @EricPFierce

@CarlyHFierce: Do reps push drugs off-label? Yes, a study suggests. Does it work? Also yes. FiercePharmaMarketing story | Follow @CarlyHFierce

@JustinHFierce: FDA voting today, tomorrow on opioid-induced constipation drug class, meds like Movantik could spell boom. More | Follow @JustinHFierce

> Novo Nordisk ($NVO) unveiled new Phase III data from a trial for its NovoEight recombinant coagulation factor that shows long-term reduction from bleeding in people with hemophilia A. Release

> Diabetics are paying about twice as much for treatment than they did a decade ago, according to Yale University researchers. Story

> Leading U.K. doctors and academics are warning the country's National Institute for Health and Care Excellence (NICE) against prescribing cholesterol-lowering statins. Article

> The U.S. federal government is divided over the use of prescription opioids for pain relief. More

> AbbVie ($ABBV) revealed results from a large global study that show that patients with more "accepting" attitudes toward their TNF inhibitors are more likely to adhere to treatment. Release

> Sanofi ($SNY) will present new clinical data about its diabetes products at the upcoming American Diabetes Association (ADA) 74th Scientific Sessions in San Francisco. Release

> Ten-year Novartis ($NVS) veteran Fabian Kausche has been appointed to lead global R&D at Sanofi's ($SNY) animal health division Merial. Release

Medical Device News

@FierceMedDev: Interesting: @Roche division @ventanamed helped shape a Dx masters degree program at @ArizonaState. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Bid for Allergan puts Valeant's research and development cuts under scrutiny. More from the WSJ (sub. req.) | Follow @VarunSaxena2

@StacyALawrence: ICYMI yesterday: FDA panel to consider first drug-eluting balloon catheter. Story | Follow @StacyALawrence

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Women who are pregnant or breastfeeding should eat at least 8 oz of fish a week, according to new #FDA guidelines. More from the NYT | Follow @EmilyWFierce

> FDA releases details of Apple device meeting in response to FOIA request. More

> FDA approves Auxogyn embryo test for IVF procedures. Article

> Study demystifies U.S. diagnostic test costs. Story

Biotech News

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Yesterday's analysis | Follow @FierceBiotech

@JohnCFierce: Lilly's key franchise drug ramucirumab flops in PhIII liver cancer study. More | Follow @JohnCFierce

@DamianFierce: Crushing realization that @Forbes' "What To Wear at BIO" feature applies solely to women. More | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday: Today's edition of Research is out. Newsletter | Follow @EmilyMFierce

> Billionaire Thiel backs biotech startups with eyes on Alzheimer's, GI disease. Report

> Old Roche R&D campus in NJ faces the wrecking ball. Item

> Hostile Allergan bid is part of Valeant's war on 'value-destroying' R&D. Story

> Rebel AstraZeneca investors push plan to tie exec pay to rosy R&D projections. Article

Pharma Marketing News

> Orexigen's weight-loss med sets up Takeda vs. Eisai marketing showdown--eventually. Article

> Feds cry foul at Allergan's free-speech defense in drug marketing case. Report

> New data backs GlaxoSmithKline's Incruse as an add-on to COPD med Breo Ellipta. Story

> Forest gives old Namenda a reprieve as switching to XR formula continues. More

> Men's Health Week or Low-T Week? Critics say awareness campaign is another pharma ploy. Article

Drug Delivery News

> UCSB study: New silver nanoparticles dissolve if they don't hit their mark. Article

> Avanir's nasal delivery for migraines beats oral sumatriptan in PhIIIb. Item

> Stem cells trapped in hydrogel better at bone repair. Story

> Cook launches Zilver PTX Drug-Eluting Stent in Canada. More

> Tonix receives IND approval for sublingual formulation to treat PTSD. Story

> Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. Article

Diagnostics News

> ImaginAb, Duke double down in Singapore on in vivo molecular imaging-agent work. More

> Roche's Ventana helped shape ASU's new Dx master's degree program. Story

> B. Braun will sell German partner's molecular Dx panels in the U.S. More

> China's FDA grants approval to Dehaier's portable sleep Dx system. Article

> AstraZeneca will tap Cancer Genetics' cancer biomarker testing tech in Central America. News

> Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test. Item

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.